Human Papillomavirus Genotype Specificity of Hybrid Capture 2

ABSTRACT Hybrid Capture 2 (hc2), a clinical test for carcinogenic human papillomavirus (HPV) DNA, has proven to be a sensitive but only modestly specific predictor of cervical precancer and cancer risk. Some of its nonspecificity for clinical end points can be ascribed to cross-reactivity with noncarcinogenic HPV genotypes. However, the reference genotyping tests that have been used for these comparisons are also imperfect. We therefore sought to describe further the HPV genotype specificity of hc2 by comparing the hc2 results to paired results from two related PGMY09/11 L1 primer-based HPV genotyping assays: Linear Array (LA) and its prototype predecessor, the line blot assay (LBA). LA and LBA results were considered separately and combined (detection by either assay or both assays) for 37 individual HPV genotypes and HPV risk group categories (carcinogenic HPV > noncarcinogenic HPV > negative). Baseline specimens from 3,179 of 3,488 (91.5%) women referred to ALTS (a clinical trial to evaluate the management strategies for women with atypical squamous cells of undetermined significance [ASCUS] or low-grade squamous intraepithelial lesions) because of an ASCUS Papanicolaou smear were tested by all three assays. Among single-genotype infections with genotypes targeted by hc2 as detected by either PCR assay, HPV genotype 35 (HPV35) (86.4%), HPV56 (84.2%), and HPV58 (76.9%) were the most likely to test positive by hc2. Among single-genotype infections with genotypes not targeted by hc2 as detected by either assay, HPV82 (80.0%), HPV66 (60.0%) (recently classified as carcinogenic), HPV70 (59.1%), and HPV67 (56.3%) were the most likely to test positive by hc2. Among women who tested negative for carcinogenic HPV by both PCR tests and were positive for noncarcinogenic HPV by either test, 28% of women were hc2 positive. Conversely, 7.8% of all hc2-positive results in this population were due to cross-reactivity of hc2 with untargeted, noncarcinogenic HPV genotypes. In conclusion, hc2 cross-reacts with certain untargeted, noncarcinogenic HPV genotypes that are phylogenetically related to the targeted genotypes, but the degree of cross-reactivity may be less than previously reported.

[1]  C Thomson,et al.  Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial , 2008, British Journal of Cancer.

[2]  J. Cuzick,et al.  Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. , 2008, Journal of the National Cancer Institute.

[3]  J. Berkhof,et al.  Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial , 2007, The Lancet.

[4]  Diane Solomon,et al.  Comparison of Linear Array and Line Blot Assay for Detection of Human Papillomavirus and Diagnosis of Cervical Precancer and Cancer in the Atypical Squamous Cell of Undetermined Significance and Low-Grade Squamous Intraepithelial Lesion Triage Study , 2007, Journal of Clinical Microbiology.

[5]  J. Dillner,et al.  Human Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer , 2008 .

[6]  Stephen D Walter,et al.  Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. , 2007, The New England journal of medicine.

[7]  Diane Solomon,et al.  2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. , 2007, American journal of obstetrics and gynecology.

[8]  Diane Solomon,et al.  2006 Consensus Guidelines for the Management of Women With Cervical Intraepithelial Neoplasia or Adenocarcinoma In Situ , 2007, Journal of lower genital tract disease.

[9]  Diane Solomon,et al.  The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. , 2007, American journal of clinical pathology.

[10]  W. Quint,et al.  Comparison of the SPF10-LiPA System to the Hybrid Capture 2 Assay for Detection of Carcinogenic Human Papillomavirus Genotypes among 5,683 Young Women in Guanacaste, Costa Rica , 2007, Journal of Clinical Microbiology.

[11]  M. Schiffman,et al.  The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. , 2007, American journal of clinical pathology.

[12]  Francisco A. R. Garcia,et al.  Pilot Study of a Commercialized Human Papillomavirus (HPV) Genotyping Assay: Comparison of HPV Risk Group to Cytology and Histology , 2006, Journal of Clinical Microbiology.

[13]  J. Cuzick,et al.  Overview of the European and North American studies on HPV testing in primary cervical cancer screening , 2006, International journal of cancer.

[14]  J. Cuzick,et al.  Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. , 2006, The Lancet. Oncology.

[15]  J. Cuzick,et al.  Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. , 2006, Journal of the National Cancer Institute.

[16]  M Arbyn,et al.  Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis , 2006, The Lancet.

[17]  L. R. Long,et al.  Age-related changes of the cervix influence human papillomavirus type distribution. , 2006, Cancer research.

[18]  C. Wheeler,et al.  A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal papanicolaou smears. , 2005, American journal of clinical pathology.

[19]  A. Tos,et al.  Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting. , 2005, American journal of clinical pathology.

[20]  S. Wacholder,et al.  Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. , 2005, The Journal of infectious diseases.

[21]  K. Straif,et al.  Carcinogenicity of human papillomaviruses. , 2005, The Lancet. Oncology.

[22]  C. Wheeler,et al.  A study of the impact of adding HPV types to cervical cancer screening and triage tests. , 2005, Journal of the National Cancer Institute.

[23]  E. Unger,et al.  Human Papillomavirus and Cervical Cancer , 2004, Emerging infectious diseases.

[24]  S. Wacholder,et al.  A population-based study of vaginal human papillomavirus infection in hysterectomized women. , 2004, The Journal of infectious diseases.

[25]  C. Peyton,et al.  Interlaboratory reliability of Hybrid Capture 2. , 2004, American journal of clinical pathology.

[26]  T. Matsukura,et al.  Human papillomavirus genomes in squamous cell carcinomas of the uterine cervix. , 2004, Virology.

[27]  Claude Fauquet,et al.  Classification of papillomaviruses. , 2004, Virology.

[28]  J. T. Cox,et al.  Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening , 2004, Obstetrics and gynecology.

[29]  U Menon,et al.  Management of women who test positive for high-risk types of human papillomavirus: the HART study , 2003, The Lancet.

[30]  Joan L. Walker.  A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. , 2003, American journal of obstetrics and gynecology.

[31]  F. X. Bosch,et al.  Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.

[32]  Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. , 2003, American journal of obstetrics and gynecology.

[33]  M. Poljak,et al.  Hybrid Capture II HPV Test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. , 2002, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[34]  A. Moscicki,et al.  American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer , 2002, CA: a cancer journal for clinicians.

[35]  Attila Lorincz,et al.  Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[36]  David R. Scott,et al.  Results of Human Papillomavirus DNA Testing with the Hybrid Capture 2 Assay Are Reproducible , 2002, Journal of Clinical Microbiology.

[37]  T. Sasagawa,et al.  Hybrid capture‐II and LCR‐E7 PCR assays for HPV typing in cervical cytologic samples , 2001, International journal of cancer.

[38]  Jack Cuzick,et al.  Detection of high‐risk HPV types by the hybrid capture 2 test , 2001, Journal of medical virology.

[39]  P. Hillemanns,et al.  Evaluation of HPV testing by Hybrid Capture II for routine gynecologic screening , 2001, Acta obstetricia et gynecologica Scandinavica.

[40]  C. Peyton,et al.  Determinants of genital human papillomavirus detection in a US population. , 2001, The Journal of infectious diseases.

[41]  M. Schiffman,et al.  Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. , 2001, Journal of the National Cancer Institute.

[42]  T. Sasagawa,et al.  High-risk and multiple human papillomavirus infections associated with cervical abnormalities in Japanese women. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[43]  L. Koutsky,et al.  Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. , 2000 .

[44]  S Wacholder,et al.  HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. , 2000, JAMA.

[45]  David R. Scott,et al.  Improved Amplification of Genital Human Papillomaviruses , 2000, Journal of Clinical Microbiology.

[46]  C. Peyton,et al.  Comparison of PCR- and Hybrid Capture-Based Human Papillomavirus Detection Systems Using Multiple Cervical Specimen Collection Strategies , 1998, Journal of Clinical Microbiology.

[47]  C. Peyton,et al.  Genotyping of 27 Human Papillomavirus Types by Using L1 Consensus PCR Products by a Single-Hybridization, Reverse Line Blot Detection Method , 1998, Journal of Clinical Microbiology.

[48]  V. Moreno,et al.  Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective , 1995 .